Episode

Success-Driven Drug Discovery with OpenBench CEO James Yoder

Podcast
Data in Biotech
Published
Feb 11, 2026
Duration seconds
3217
Processing state
not_requested
Canonical source
https://www.corrdyn.com/
Audio
https://downloads.pod.co/5fac40cd-043b-485f-838d-c63fa01ae1b2/34e29044-9bef-4d6c-9298-cc053158c9d4.mp3
JSON
/v1/public/podcasts/data-in-biotech-6628050/episodes/success-driven-drug-discovery-with-openbench-ceo-james-yoder
Markdown
/podcast/data-in-biotech-6628050/success-driven-drug-discovery-with-openbench-ceo-james-yoder.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/data-in-biotech-6628050/episodes/success-driven-drug-discovery-with-openbench-ceo-james-yoder/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/data-in-biotech-6628050/success-driven-drug-discovery-with-openbench-ceo-james-yoder.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of Data in Biotech , host Ross Katz sits down with James Yoder, Founder and CEO of OpenBench, to unpack a radical new approach to early-stage drug discovery. James shares how OpenBench's "success-driven" model shifts risk away from biotech partners by only charging for validated hits. They dive deep into computational screening, molecular modeling, and the company's evolving tech stack that's making hit discovery smarter and more accessible. Discover how data, AI, and strategic collaboration are redefining biotech R&D. What you'll learn in this episode: >> Why OpenBench moved away from SaaS to a success-based service model >> How their computational platform predicts binding affinity and screens trillions of compounds >> The role of data flywheels and ML in improving drug discovery success rates >> Real-world case studies from biotech collaborations >> How OpenBench evaluates druggable targets in one week Meet our guest James Yoder is the Founder and CEO of OpenBench. With a background in statistics, data science, and applied machine learning, he leads OpenBench's mission to deliver validated drug discovery hits through computational innovation and a success-driven business model. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancy Connect with James Yoder on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science. Subscribe and leave a review if you enjoyed this episode! Connect with Ross Katz on LinkedIn Sponsored by… This episode is…